medigraphic.com
ISSN 1561-3119 (Electronic)

2020, Number 4

<< Back Next >>

Rev Cubana Pediatr 2020; 92 (4)

Therapeutic challenges in the idiopathic nephrotic syndrome

Durán ÁS

Language: Spanish
References: 47
Page: 1-18
PDF size: 456.35 Kb.


ABSTRACT

Diagnosis, evaluation and treatment of nephrotic syndrome in children dates from Hypocrate times. However, nowadays some patients with this disease are still a therapeutic challenge for physicians. The aim of this work is to search in recent literature different proposals or treatment protocols, and new drugs that can be used in the care of patients with this disease. Treatment protocols vary with relative frequency and drugs, as well as in frequent relapsing nephrotic, corticodependent or corticoresistant syndromes, do not guarantee in many ocassions the cure of the patient. When steroids fail, alkylanting agents, calcineurin depressants, antispreading, monoclonal antibodies and other drugs can be ussed; but there are patients who do not have remission of proteinuria with any of these treatments. Due to their evolutive characteristics, some patients with idiopathic nephrotic syndrome are still a challenge for the physicians who try to avoid its evolution toward the loss of renal function. Although all the advances in the care of children with nephrotic syndrome due to the discover of steroids, antibiotics, diuretics and immunosupressive drugs, nowadays we do not exactly know which is the best treatment for the resistant types of idiopathic nephrotic syndrome in children.


REFERENCES

  1. Cil O, Perwad F. Monogenic causes of proteinuria in children. Front Med. 2018; 5:e2551. doi: http://doi.org/10.3389/fmed.2018.00055

  2. Nandi M, Mandal SK, Samanta M, Majdi A, Efficacy of mycophelonate mofetil as remission maintanancing agent in idiopathic nephrotic children. Indian J Nephrol. 2019;29:34-41.

  3. Trautman A, Schnsidt S, Lipska-Zierkiewics BS, Bodria A, Ozaltin F, Emma F, et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol. 2017;28:3055-65.

  4. Cattran DCP. Long-term outcome in children and adults with classic focal segmental glomeruloesclerosis. Am J Kidney Dis. 1998;32:72-9.

  5. Hinkes BG, Mucha B, Vlangos CN, Gbadagesin R, Lin J, Hasselbacher K, et al. Nephrotic syndrome in the first year of life: Two thirs of cases are caused by mutation in 4 genes (NPHS1, NPHS2, WT1 and LAMB2). Pediatrics. 2007;119:e907-19.

  6. McCaffrey J, Lennon R, Webb NJA. The non-immunosuppressive management of childhood nephrotic syndrome. Pediatr Nephrol. 2016;31:1383-402.

  7. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Eur J Pediatr. 1993;152:357-61.

  8. Han K, Kim SH. Recent advances in treatments of primary focal segmental glomeruloesclerosis. Bio Med Int. 2016;2016:3053706. doi:10.1155/2016/3053706. Epub: 2016 Apr 18.

  9. Sethna CB, Gipson DS. Treatment of FSGS in children. Arch Chron Kidney Dis. 2014;21:194-9.

  10. Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MS, et al. Management and treatment of glomerular diseases (Part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95:281-95.

  11. Velásquez-Jones L. Treatment of idiopathic nephrotic syndrome in children (English edition). Bol Med Hosp Inf Mex. 2014;71:315-27.

  12. KDIGO, Clinical practice guidelines for glomerulonephritis. Kidney Int. 2012 (Suppl 2):139-74.

  13. Baltar Martin JM, Ortega F,.Ciclofosfamida en glomerulonefritis primarias y secundarias. Nephroplus. 2002;3:9-15.

  14. Ballona Chambergo R. Inhibidores de la calcineurina: Una alternativa en el tratamiento inmunosupresor. Dermatol Peruana. 2003;13:121-3.

  15. Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change Disease. Clin J Am Soc Nephrol. 2017;12:332-45.

  16. Kengne-Wafo S, Massella L, Diomedi-Camassei F, Giavinti A, Vivarelli M, Greco M, et al. Risk factors for cyclosporine A nephrotoxicity in children with steroid-dependent nephrotic syndrome. Clin J Am Soc Nephrol. 2009;4:1409-16.

  17. Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, et al. Evidence-based clinical practice for nephrotic syndrome 2014. Clin Exp Nephrol. 2016;20:342-70.

  18. Ehren R, Benz MR, Doetsch J, Fichtner A, Gallerman J, Haffner D, et al. Initial treatment of steroid-sensitive nephroti syndrome in children with mycophelonate mofetil versus prednisone: Protocol for a randomized controlled multicenter trial (INTENT Study). BJM Open. M2018;e24882. doi:10.1136/bmjopen,2018-014882.

  19. Sandoval D, Poveda R, Draibe J, Perez-Oller C, Diaz M, Ballarin J, et al. Efficacy of mycophelonate mofetil in adults with steroid-dependent/frequent relapsing idiopathic nephrotic syndrome. Clin Kidney J. 2017;10:632-8.

  20. Sinha A, Paraswani M, Gomal P, Hari P, Bagga A. Efficacy and safety of mycophelonate mofetil versus levamisol in frequent relapsing nephrotic syndrome: An open-label randomized controlled trial. Kidney Int. 2019;95:210-8.

  21. Querfeld U, Webber LT. Mycophelonate mofetil for sustained remission in nephrotic syndrome. Pediatr Nephrol. 2018;33:2253-5.

  22. Kim SH, Lim TJ, Song JY, Kim SY. Effects of Rituximab including long-term maintenance therapy in children with nephrotic syndrome in a single center of Korea. Child Kidney Dis. 2018;22.1-6.

  23. Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017;21:193-202.

  24. Kallas M, Smoyer WE, Mahan US. Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr. 2020;7:178. doi: 10.3389/fped.2019.00178 Epub: 2019 May.

  25. Lombel RM, Hodson EM, Gipson DS, Treatment of steroid resistant nephrotic syndrome in children: New Guidelines from KDIGO. Pediatr Nephrol. 2013;28:409-14.

  26. Shalhoub RJ. Pathogenesis of lipoid nephrosis: A disorder of T-cell. Lancet. 1974;2:556-60.

  27. Takahashi T, Okamoto T, Sato Y, Amazaki T, Hamashi A, Aomagi H, et al. Periodically repeated rituximab administration in children with refractory nephrotic syndrome: 2 year multicenter observation study. Pediatr Nephrol. 2019;34:87-96.

  28. Jellouli M, Charfi R, Maales B, Mahfoud A, Trabesi S, Gargah T. Rituximab in the management of pediatric steroid-resistant and dependent nephrotic syndrome: A systematic review. J Pediatr. 2018,197:191-7.

  29. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and dependent nephrotic syndrome: Multicenter report. Clin J Am Soc Nephrol. 2010;5:2207-12.

  30. Wang GS, Liverman RS, Garro R, George RP, Glumova A, Karp A, et al. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol. 2017;32:835-41.

  31. Bonnani A, Rossi R, Murtas C, Ghicgen M. Low dose ofatumumab for resistant nephrotic syndrome. BMJ Case Rep. 2015. doi:10.1136/bcr-2015-210208. Epub: 16 sept 2015.

  32. Choi J, Jordan S, Vo A. First experience with rituximab (type II anti-CD20) in patients with treatment-resistant glomerulonephritis disease and antibody mediated rejection. Am J Transplant. 2016 [acceso 28/08/2019.;16(Suppl 3). Disponible en: https;//actcmeeringabstract/first-experience-with-obitumumab-type-anti-cd20-in-patients-with-treatment-resistant-glomerular-disease-and-antibody-mediated-rejection

  33. Joy MS, Gipson DS, Powell L, MacHardy K, Jennette JC, Vento S, et al. Phase 1 trial of aladimumab in focal segmental glomeruloesclerosis (FSGS). Report of of the FONT (Novel Therapies for Resistant FSGS Syndrome Study Group. Am J Kidney Dis. 2010;55:55-60.

  34. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DRW, Peters H, et al. A phase I, single-dose study of fresolumimab: an anti TGF-B antibody, in treatment-resistant primary focal segmental glomeruloesclerosis. Kidney Int. 2011;79:1236-43.

  35. Williams CA. Encyclopedia of food sciences and nutrition, 2nd ed. Cambridge, Massachusetts: Academic Press, Book & E-Book; 2003.

  36. Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M. Galactose binds to focal segmental glomeruloesclerosis permeability factor-associated and inhibits its activity. Transl Res. 2008;151:288-92.

  37. De Smet E, Rious JP, Ammann H, Deziel C, Querin S. FSGS permeability factor-associated nephrotic syndrome remission after oral galactose therapy. Nephrol Dial Transplant. 2009;24:2938-40.

  38. Sgambat K, Banks M, Moudgil A. Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2013;28:2131-5.

  39. Kopac M. Nephrotic syndrome in children - present state and future perspectives. J Nephrol Res. 2018;4:139-45.

  40. Kopac M, Meglic A, Rus RR. Partial remission of resistant nephrotic syndrome after oral galactose therapy. Ther Arher Dial. 2010;15:269-72.

  41. Mishra OP, Singh AK, Pohl M, Kumar G. Oral galactose in children with focal segmental glomeruloesclerosis: A novel adjunct therapy. Clin Kidney J. 2014;7:83-5.

  42. Robson K, Hill P, Longsford D, Dwyer K, Langham R. Galactose therapy reduces proteinuria patients with recurrent focal segmental glomeruloesclerosis after kidney transplantation. Nephrology (Carlton). 2015;(suppl 1):13-6. doi:10.1111/nep724.72.

  43. Barnett HL, Forman CW, McNamara H, McCroy WW, Rapoport M, Michie R, et al. The effect of adrenocortitropic hormone in children with nephrotic syndrome. II. Physiological observation on discrete kidney functions and plasma volume. J Clin Invest. 1952;30:227-35.

  44. Hogan HC, Bomback AS, Mehta K, Canetta PA, Rao M, Appel GB, et al. Treatment of idiopathic FSGS with adrecorticotropic hormone gel. Clin J Am Soc Nephrol. 2013;8:2072-8.

  45. Imaizumi T, Kawasaki Y, Matsuvra H. Efficacy of steroid pulse, plasmapheresis, and mizoribine in a patient with focal segmental glomerulosclerosis. Pediatr Nephrol. 2007;22:1215-7.

  46. Aizagua Y, Yashiro T, Tsuruga K, Watanabe S, Okie K, Ito E. Novel multidrug therapy for children with cyclosporine-resistant or- intolerant nephrotic syndrome. Pediatr Nephrol. 2011;26:1255-61.

  47. Pal A, Kaskel F. History of nephrotic syndrome and evolution of its treatment. Front Pediatr. 2016;4:56. doi:10.3389/fped.2016.00056.




2020     |     www.medigraphic.com